Moreover, both the CF1 and total TI Treg signatures had superior discrimination ability when compared to previously reported tumor Treg markers, such as FOXP3 and ratio-based signatures CCR8:FOXP3 or CCR8:CD3G (Fig. 3c)12,13. This evidence concerns the gene CD3G and neoplasm.